Agios Pharmaceuticals to Present New Research at the 12th International Congress of Inborn Errors of Metabolism
“We are eager to participate in this important conference, and look
forward to the opportunity to collaborate with world leaders in the
scientific understanding of inborn errors of metabolism,” said
The schedule for Agios’ presentations is as follows:
Date & Time: |
Wednesday, September 4, 2013 at 1:00 – 2:00p.m. CEST |
|
Session Type: |
Poster presentation |
|
Presentation Title: |
P-251 Small molecule inhibition of IDH2(R140Q) in lymphoblasts |
|
|
of D-2-hydroxyglutaric aciduria type II patients |
|
Presenter: |
Kimberly S. Straley, scientist, biology |
|
Location: |
Poster Hall, Level-1 |
Date & Time: |
Thursday, September 5, 2013 at 12:15p.m. CEST | |
Session Title: |
Workshop 6 – The Potential of Model Systems to Understand Inborn | |
Errors of Metabolism | ||
Session Type: |
Oral presentation | |
Presentation Title: |
W-020. Mice with IDH2 (p.R140Q) knock-in mutation modeling human | |
type II D-2-hydroxyglutaric aciduria | ||
Presenter: |
Shengfang Jin, Ph.D., senior director, biology | |
Location: |
Room F |
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. The
words “believe,” “expect” “could,” “should,” “will,” “may” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Such statements are subject to important risks and uncertainties
that may cause actual events or results to differ materially from Agios’
current expectations and beliefs, including the risks described under
the caption “Risk Factors” in Agios’ Registration Statement on Form S-1
which was declared effective by the
Source:
Agios Pharmaceuticals, Inc.
Media Contact:
Dan Budwick,
973-271-6085
dan@purecommunicationsinc.com
or
Investor
Contact:
Glenn Goddard
investors@agios.com